Our discovery platform can identify compounds that potently block the progression of amyloid toxicity. These compounds can be designed with selectivity toward a particular misfolding protein (narrow spectrum) or with polypharmocology (broad spectrum), for proteins implicated in over 160 rare/orphan diseases and major indications including
